Patent · US Active

BAG3 as a target for therapy of heart failure

US11236389B2 · kind B2 · utility

0Cited by

0References

23Claims

0Family size

Assignee

Temple University-Of The Commonwealth System of Higher Education · US

Inventors

Arthur M. Feldman · Pittsburgh, US
Douglas G. Tilley · Via Enrico Fermi, US
Weizhong Zhu · Hartsdale, US
Kamel Khalili · Yeadon, US
Walter J. Koch · Durham, US

Key dates

Filing date	Jan 30, 2015
Grant date	Feb 1, 2022
Priority date	—
Expiry date	Jan 30, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/50
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.